Lei Zhao

Dr. Lei Zhao

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 October 2024 in Cancers
Verified
Journal Article
Open access
PDF file
LZLei Zhao
Lei Zhao
JSJack Shireman
Jack Shireman
SPSamantha Probelsky
Samantha Probelsky
BRBailey Rigg
Bailey Rigg
XWXiaohu Wang
Xiaohu Wang
MDMahua Dey
Mahua Dey
Dendritic cells (DCs) are professional antigen-presenting cells that are traditionally divided into two distinct subsets: myeloid DCs (mDCs) and plasmacytoid DCs (pDCs). pDCs are known for their ability to secrete large amounts of cytokine type I interferons (IFN- α). In our previous work, we have demonstrated that pDC infiltration promotes glioblastoma (GBM) tumor immunosuppression through decreased IFN-α secretion via TLR-9 signaling and increased suppressive function of regulatory T cells (Tregs) via increased IL-10 secretion, resulting in poor overall outcomes in mouse models of GBM. Further dissecting the overall mechanism of pDC-mediated GBM immunosuppression, in this study, we identified CCL21 as highly upregulated by multiple GBM cell lines, which recruit pDCs to tumor sites via CCL21-CCR7 signaling. Furthermore, pDCs are activated by CCL21 in the GBM microenvironment through intracellular signaling of β-arrestin and CIITA. Finally, we found that CCL21-treated pDCs directly suppress CD8+ T cell proliferation without affecting regulatory T cells (Tregs) differentiation, which is considered the canonical pathway of immunotolerant regulation. Taken together, our results show that pDCs play a multifaced role in GBM immunosuppression, and CCL21 could be a novel therapeutic target in GBM to overcome pDC-mediated immunosuppression.

1 July 2022 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
LZLei Zhao
Lei Zhao
THTony Hsiao
Tony Hsiao
CSConnor Stonesifer
Connor Stonesifer
JDJay Daniels
Jay Daniels
TGTiffany J. Garcia-Saleem
Tiffany J. Garcia-Saleem
GWGary S. Wood
Gary S. Wood

2 August 2026 in Organoids
Verified
Journal Article
Open access
PDF file
NYNina Y Yuan
Nina Y Yuan
WRWilliam Richards
William Richards
KPKailyn T Parham
Kailyn T Parham
KGKaylie Greuel
Kaylie Greuel
JZJoshua A. Zimmermann
Joshua A. Zimmermann
CLConnie Stechmann Lebakken
Connie Stechmann Lebakken
Glioblastoma (GBM) is a highly aggressive malignant brain tumor accounting for 15% of all brain tumors and 50% of all gliomas. The exact cause of GBM is not fully understood but risk factors include age, genetic mutations, exposure to ionizing radiation, and certain genetic disorders. Symptoms of GBM include headaches, seizures, cognitive impairment, and weaknesses on one side of the body. Myeloid cells account for 30–50% of the tumor mass and are instrumental in shaping the complex tumor microenvironment (TME). Inflammation in the TME is an important driver of tumor growth and invasion; however, as the environment evolves, the immunosuppressive TME poses a significant hurdle as it hinders the immune-mediated killing of tumor cells. Our work utilizes neuroimmune organoids containing neurons, astrocytes, microglia, and vascular-like cells, to which we add patient-derived GBM cells and/or iPSC-derived macrophages to model the GBM TME. Model characterization was performed using single-cell RNA sequencing and supernatant proteomics to determine cell-specific changes during coculturing. Our findings are consistent with this 7-day coculture model recapitulating key aspects of GBM early tumor establishment and immune activation, with transcriptomic and secretome signatures suggestive of an emerging immune evasion phenotype.

2 May 2026 in Neuro-Oncology
Verified
Journal Article
Closed access
LZLei Zhao
Lei Zhao
PCPaul Clark
Paul Clark
JSJack Shireman
Jack Shireman
CSCheyenne L Schepp
Cheyenne L Schepp
HRHansel Comas Rojas
Hansel Comas Rojas
MDMahua Dey
Mahua Dey
Background: Leptomeningeal metastasis from a solid tumor carries a dismal prognosis with median survival of 3-5 months after diagnosis and treatment with external beam radiation therapy. It targets the whole-brain or the entire central nervous system depending on disease extent, and is the current standard therapeutic approach, however, its effectiveness is limited by insufficient cytotoxicity and severe off target radiotoxicity. Methods: Radiopharmaceutical therapy is a promising strategy to deliver therapeutic radiation doses directly to the leptomeningeal space while minimizing damage to the normal central nervous system tissue. In this study, the tumor targeting alkylphosphocholine (NM600) was radiolabeled with 177Lu for SPECT/CT imaging and 225Ac for therapeutic efficacy in the context of solid tumor leptomeningeal metastasis. Results: In in vitro experiments 225Ac-NM600 induced significantly greater apoptosis, reduced colony formation, and increased expression of DNA damage markers, compared to 177Lu or external beam radiation. In vivo therapeutic and toxicity profiles were assessed in leptomeningeal metastasis models of triple negative breast cancer and non-small cell lung cancer in NSG mice. Intrathecal administration of 177Lu- or 225Ac-NM600 demonstrated excellent tumor targeting with minimal off target effect, confirmed by SPECT/CT imaging and ex vivo biodistribution. 225Ac-NM600 was well tolerated, inhibited tumor growth, and significantly improved overall survival in both models. Moreover, central nervous system radiotoxicity was markedly lower with 225Ac-NM600 RPT compared to external beam radiation therapy. Conclusions: Compared with whole brain external beam radiation therapy, 225Ac-NM600 provides superior anti-tumor efficacy and reduced off target toxicity supporting its further evaluation in clinical trial.